Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

AbbVie

Tracked across 32 events · 364 articles · First seen Apr 17, 2025 · Last active Sep 22, 2026

Sentiment
12
Attention
8
Events
32
Relationships
8
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: AbbVie has deployed its wealth planning platform at Belgium, strengthening its position in the European banking market and expanding its reach to Personal Banking clients.
Jun 11, 2026 · 6 articles
2 60
Regulatory
Impact: AbbVie's RINVOQ received its first global approval for vitiligo, expanding its therapeutic indications and potentially boosting revenue, while strengthening its immunology portfolio.
Aug 17, 2026 · 6 articles
4 75
Tech
Impact: AbbVie>>> developed Mirvetuximab soravtansine, the new ovarian cancer drug. The approval of Mirvetuximab soravtansine by the United Kingdom — National Health Service>>> is a major commercial success for AbbVie>>>, potentially boosting its revenue and stock value.
Jun 03, 2026 · 9 articles
6 -30
International
Impact: AbbVie is being investigated by the United States — House Select Committee on the Chinese Communist Party regarding its clinical trials in China, especially in China — Xinjiang and at military hospitals. This investigation highlights ethical and security risks for AbbVie and could lead to negative market sentiment and regulatory challenges.
Apr 20, 2026 · 8 articles
2 40
Business
Impact: AbbVie is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
2 10
Business
ADARx Pharmaceuticals, a San Diego-based developer of RNA-based drugs for rare immune, kidney, cardiovascular and neurological diseases, announced on September 21, 2026 that it is seeking a valuation of up to $1.74 billion in its…
Impact: Agreed to invest up to $100 million in a concurrent private placement for a roughly 4.9% post-IPO stake, deepening an existing collaboration after a $335 million payment in May 2025. The move signals continued big-pharma appetite for external innovation.
Sep 21, 2026 · 6 articles
2 50
Business
Impact: AbbVie achieved third and fourth research milestones under its collaboration with Nxera, resulting in US$20 million in milestone payments to Nxera. This reflects progress in neurological disease programs.
Aug 07, 2026 · 6 articles
2 10
Business
Cloverleaf Bio, an RNA therapeutics company spun out of Yale University and headquartered in New Haven, Connecticut, closed an upsized and oversubscribed $33 million seed financing round. The round was led by 4BIO Capital and…
Impact: Its venture arm AbbVie Ventures participated strategically in the round, giving it early exposure to Cloverleaf's tRNA platform and potential optionality in RNA-based oncology.
Sep 08, 2026 · 6 articles
6 0
Regulatory
Impact: AbbVie is expected to announce a deal with the Donald Trump administration after the holidays.
Dec 19, 2025 · 7 articles
2 5
Regulatory
Women are increasingly seeking testosterone therapy for menopause symptoms, but face prescription delays and denials at major pharmacies. There is no U.S.-approved testosterone product for women, though off-label use has surged 146% from January 2023…
Impact: AbbVie's AndroGel is among testosterone products used off-label by women, potentially benefiting from increased demand.
Sep 15, 2026 · 6 articles
2 10
Business
Iambic Therapeutics, a San Diego-based drug developer backed by Nvidia and the Qatar Investment Authority, filed for a US initial public offering on Monday, September 21, 2026, aiming to list on the Nasdaq under the…
Impact: Entered a multi-year collaboration with Iambic to accelerate AI-driven discovery of small molecule therapies, expanding its early-stage pipeline.
Sep 21, 2026 · 6 articles
6 10
Tech
Impact: AbbVie Inc. is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.
Feb 19, 2026 · 6 articles
3 10
Tech
Impact: Employer of Marc Weinberg; not involved in the study, but associated through employee.
Jul 06, 2026 · 6 articles
4 50
Business
Impact: AbbVie's acquisition of Apogee Therapeutics is part of the M&A activity boosting biotech valuations and investor sentiment.
Jul 06, 2026 · 25 articles
2 0
Regulatory
Impact: AbbVie, through its acquisition of ImmunoGen, is a collaborator in the discovery of Varseta-M, but this event has minimal direct impact on AbbVie.
Aug 27, 2026 · 6 articles
8 0
Business
Impact: AbbVie is mentioned as a developer of an approved BTK inhibitor, Imbruvica, which is a competitor to bexobrutideg.
Jun 07, 2026 · 22 articles
2 0
Business
Impact: AbbVie is a joint venture partner in Abbvie Therapeutics India Private Limited, mentioned as an associate company.
Jul 07, 2026 · 14 articles
3 0
Regulatory
Impact: AbbVie now owns the brand Pred Forte, but is not directly affected by the recall of the generic version.
Jul 07, 2026 · 38 articles
2 0
Business
Impact: Mentioned as partner in a joint venture with Piramal Pharma; not directly impacted by this expansion.
Aug 04, 2026 · 12 articles
2 0
Business
Impact: Mentioned as partner in an associate company; not directly impacted by this acquisition.
Jul 20, 2026 · 11 articles
2 0
Business
Impact: AbbVie is mentioned as a joint venture partner in Abbvie Therapeutics India Private Limited, an associate company of Piramal Group. The report does not detail any direct impact on AbbVie, but the association highlights a successful collaboration in the ophthalmology market.
Jul 20, 2026 · 12 articles
6 0
Business
Impact: Mentioned as part of 2026 M&A activity; acquired Apogee for $10.9B.
Jul 06, 2026 · 34 articles
4 0
Business
Impact: AbbVie is a competitor that previously acquired KC Pharmaceuticals for up to $1.2B in 2024, highlighting industry interest in psychedelic therapies.
Jul 16, 2026 · 25 articles
2 0
Business
Impact: AbbVie is a joint venture partner in Abbvie Therapeutics India Private Limited, mentioned as an associate company.
Jul 29, 2026 · 10 articles
0 0
Business
Impact: Ramakrishna Venugopalan previously led combination product drug development at AbbVie; the event does not directly affect AbbVie.
Jul 30, 2026 · 6 articles
4 0
Business
Impact: AbbVie is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Sep 04, 2026 · 12 articles
1 0
Business
Piramal Group Solutions (PPS), the contract development and manufacturing arm of Piramal Group, is installing a 4.3 MWp ground-mounted solar power plant at its integrated drug substance and drug product facility in Morpeth, United Kingdom.…
Impact: AbbVie is only mentioned as Piramal Group's joint venture partner in Abbvie Therapeutics India and plays no role in this solar project. The event has no material effect on AbbVie.
Sep 16, 2026 · 13 articles
4 0
Tech
Apr 12, 2026 · 7 articles
4 0
Business
Apr 22, 2026 · 6 articles
2 0
Business
Apr 30, 2026 · 7 articles
+ 2 more events View on Dashboard
Coeptis Therapeutics Holdings none ↔ AbbVie AbbVie does not have a direct business relationship with Coeptis Therapeutics Ho
Bain Capital no direct relation ↔ AbbVie AbbVie acquired Cerevel Therapeutics, a company in which Bain Capital was a majo
Coeptis Therapeutics Holdings none ↔ AbbVie Coeptis Therapeutics Holdings does not have a direct business relationship with
Bain Capital no direct relation ↔ AbbVie Bain Capital was a major investor in Cerevel Therapeutics, which AbbVie acquired
ERGEN INTELLIGENCE
Track AbbVie live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.